If China gets 7/10 in pharma policy, India scores 2

The managing director of Pfizer India, Kewal Handa shares his reservations on the country’s emerging pharma policy landscape in an interview with FE’s Soma Das. Excerpts. What are your apprehensions on the new pharma pricing policy? A good part of the new pharma pricing policy is progressive. For instance, the entire shift of the policy to being more market driven, inclusion of clinical trials under weighted deduction benefit and the move to regulate prices of formulations rather than bulk drugs is commendable. However, preserving the scope of the national list of essential medicine (NLEM) is the most critical aspect here.

Read Full Story>>